Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial

We recently published 11 Best Cancer Stocks to Buy Right Now. Arcellx, Inc. stands sixth among them.

Arcellx, Inc. (NASDAQ:ACLX) is a biotechnology company developing next-generation cell therapies to treat cancer and incurable diseases, with a focus on improving the safety and efficacy of CAR-T treatments through its proprietary D-Domain and ddCAR platforms.

Its lead candidate, anitocel, for multiple myeloma has shown exceptional Phase 2 trial results, with a 97% overall response rate and 93.1% minimal residual disease (MRD)-negative responses. Importantly, the therapy demonstrated a favorable safety profile, avoiding severe neurotoxicity often associated with CAR-T treatments. Over 150 patients have been treated, with long-term data confirming strong efficacy and tolerability. To align with FDA guidance, Arcellx, Inc. has updated its iMMagine-3 study protocol to include MRD negativity alongside progression-free survival as dual primary endpoints, aiming to accelerate regulatory approval and patient access.

The company will present updated results from 117 patients in the iMMagine-1 trial at the European Hematology Association (EHA) 2025, reinforcing its commitment to transparency and innovation. A commercial launch of anito-cel is targeted for 2026, supported by new leadership additions to strengthen operational and strategic execution.

Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial

A medical professional in a hospital, using targeted cancer therapuetics to treat cancer patients.

The business has also expanded its partnership with Kite (a Gilead company) to co-develop and co-commercialize CAR-T programs for multiple myeloma and lymphoma. The collaboration, backed by significant funding, underscores confidence in Arcellx, Inc.’s pipeline and its potential to address high unmet needs in oncology.

Beyond anito-cel, the corporation is advancing programs like ACLX-001 (ARC-SparX), designed to enhance flexibility and control in CAR-T therapies.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.